Allergies, including atopic dermatitis (AD), are multifactor diseases, and the pathogenic mechanism is not fully understood yet. It is possible that indoor environmental changes, particularly alterations in our living conditions, have led to sympton primarily caused by Volatile Organic Compounds (VOCs). Previously, due to high levels of VOCs emitting from building materials, newly constructed residences were notably associated with the onset of 'sick house syndrome'. Intriguingly, these compounds continue to emit gases even after the disappearance of their characteristic odors. In our previous investigations identified that a Chemical Filter (CF) can effectively mitigate about 90% of VOCs, which subsequently led to a significant suppression in trans epidermal water loss and skin thickness during AD's early phases in murine models. Although the VOC removal indicated potential benefits in thwarting the onset of allergies, its synergy with pharmacological interventions remained uncharted. This study delves into the efficacies of Janus kinase (JAK) inhibitors, a drug aimed at alleviating AD-associated itching. Our results suggest a notable reduction in itch frequency and auricular lymph node cell counts within the CF group, suggesting potential symptom alleviation. This study suggests that reducing VOCs could play a crucial role in AD prevention and treatment strategies.